Travere Therapeutics, Inc. TVTX
59.44
(1.18)
(1.95%)
as of 25 Sep
- Market cap
- $5.7B
- P/E
- 0.0×
Follow TVTX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(410.76%) | (29.38%) | (32.57%) | (151.79%) | |
| (16.98%) | (4.26%) | (3.88%) | (6.42%) | ||
ROIC |
(43.68%) | (37.84%) | (24.41%) | (18.31%) | |
Return on Tangible Assets |
(36.84%) | (9.07%) | (7.91%) | (9.32%) | |
Average Days of Receivables |
69.50 | 59.60 | 59.43 | 49.77 | |
Free Cash Flow per Share |
(1.21) | (0.23) | (0.31) | 0.16 | |
Free Cash Flow |
(107.87) | (20.37) | (28.94) | 15.16 | |
Capital Expenditures |
(49.25) | (58.16) | (68.55) | (77.54) | |
Piotroski F-Score |
6.00 | 7.00 | 7.00 | 6.00 | |
| Other line items | |||||
Cash ROIC |
(9.17%) | 5.04% | 5.86% | 8.30% | |
Accounts Receivable Turnover |
8.06 | 9.15 | 8.81 | 9.91 | |
Accounts Payable Turnover |
0.50 | 0.43 | 0.54 | 0.62 | |
Inventory Turnover |
1.74 | 1.71 | 1.48 | 1.39 | |
Average Days of Payables |
643.46 | 875.52 | 619.30 | 331.08 | |
Days of Inventory on Hand |
195.88 | 207.41 | 304.85 | 346.09 | |
Tax Rate |
0.00 | 0.02 | 0.02 | 0.01 | |
Research and Development Expense of Revenue |
48.08% | 41.98% | 40.32% | 38.41% | |
Selling, General and Administrative Expense of Revenue |
64.00% | 68.71% | 66.59% | 66.05% | |
Share Based Compensation of Revenue |
9.78% | 9.14% | 9.24% | 10.26% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.66 | (1.48) | (1.85) | (2.13) | |
Depreciation/Fixed assets |
12.01 | 14.41 | 19.40 | 18.75 | |
Capex/Depreciation |
(0.95) | (1.00) | (0.97) | (1.28) | |
Revenue per Share |
4.88 | 5.50 | 5.84 | 6.33 | |
Operating CF per Share |
(0.66) | 0.42 | 0.43 | 0.99 | |
Capex per Share |
(0.55) | (0.65) | (0.75) | (0.83) | |
Capex to Sales |
0.11 | 0.12 | 0.13 | 0.13 | |
Net Profit Margin |
(20.32%) | (5.21%) | (4.00%) | (7.35%) |
Columns are period end dates